Clinical Trial

A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Relapsing/Refractory Multiple Sclerosis

Name: A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Relapsing/Refractory Multiple Sclerosis — clinical trial record (NCT07748637)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

This is a single-arm, open-label, dose-escalation clinical trial intended to evaluate the safety, efficacy and cellular pharmacokinetics of GT802 for the treatment of relapsing/refractory multiple sclerosis.

Trial Details

NCT Number	NCT07748637
Lead Sponsor	Daishi Tian Collaborators: Vivacta Biotechnology (Shanghai) Co., Ltd.
Conditions	Multiple Sclerosis (MS)
Enrollment	12 participants
Start Date	2026-08-15
Primary Completion	2031-07-30 (estimated)
Study Completion	2031-07-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-06